Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC2ADVANCE
NCT07538401Phase 2Not yet recruiting
- Sponsor
- University Health Network
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of asciminib in chronic myeloid leukemia (CML), sponsored by University Health Network. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07538401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538401.